What is Thiolanox®

Novoteris is focused on developing inhaled nitric oxide gas formulations to address some of the most serious and lethal respiratory tract infections. Our scientists have spent two decades studying and developing nitric oxide for the treatment of drug resistance infections in diseases such as tuberculosis, cystic fibrosis, bronchiectasis, and chronic sinus disease.

Thiolanox® is a pharmaceutical nitric oxide gaseous formulation supplied in high pressure cylinders at 5,000 ppm (0.5% v/v) blended with medical grade nitrogen. It is an investigational drug product that is being studies as an inhaled product for the treatment of airway colonization in patients with cystic fibrosis (CF). Thiolanox® is not approved for sale in the United States.

Inhaled Nitric Oxide Delivery Device

The Novoteris Inhaled Nitric Oxide Delivery Device (INODD) is a custom computerized trace-gas delivery device designed for the specific application of delivering a fixed concentration of 160-ppm nitric oxide to patients with cystic fibrosis and other respiratory infections as part of Novoteris’ anti-infective clinical trials. The INODD is capable of delivering this high concentration of nitric oxide without the need for adding oxygen.